
    
      A prospective, multi-center, double-blind, randomized, parallel-group clinical study.

      The study will comprise the following periods:

      I. Screening + randomization + treatment initiation: Visit 1 (Day 1) II. Blinded treatment
      with LRG-002 or matching placebo in antibiotic-treated patients for a total of 14 days.
    
  